New evidence of stem cells' pivotal role in cancer shown in Stanford study

December 22, 2010

STANFORD, Calif. - Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

"The clinical implications of this concept are huge," said acting assistant professor of oncology Ash Alizadeh, MD. "If we're not able to design therapies to target this self-renewing population of chemotherapy-resistant cells, the patients will continue to have a tendency to relapse." And yet, although much laboratory evidence exists to support the idea, clinical evidence to support the cancer stem cell hypothesis has until now been sparse.

Alizadeh is a co-senior author of the research, which will be published Dec. 22 in the Journal of the American Medical Association. Senior researcher Andrew Gentles, PhD, is the first author. Alizadeh and Gentles teamed up with assistant professor of hematology Ravindra Majeti, MD, PhD, and associate professor of radiology Sylvia Plevritis, PhD, to conduct a retrospective analysis of more than 1,000 patients with acute myeloid leukemia who were treated at centers in the Netherlands, Germany, Japan and the United States including Stanford Hospital & Clinics. Alizadeh, Majeti and Plevritis are members of the Stanford Cancer Center. Majeti is the other co-senior author.

The cancer stem cell hypothesis has gained increasing credence as researchers from around the world have identified subpopulations of cells in a variety of solid and blood cancers that resist treatment and contribute to relapse in animal models. Eradicating these stem cells is necessary, many believe, for a complete cure. But studies in animals are still several steps removed from proving the idea's worth in humans.

"What's been lacking is clinical evidence that these observations in mice impact actual outcomes in human patients independently of existing prognostic factors," said Majeti. "We wanted to know, 'Do genes associated with leukemia stem cells confer a bad prognosis for a patient?'"

In September, Majeti and Alizadeh showed that targeting a protein called CD47 found on the surface of cancer stem cells in combination with another antibody could eliminate human non-Hodgkin lymphoma in laboratory mice. CD47, which has been dubbed a "don't eat me" signal that protects the cells from elimination by the host's immune system, has also been found on stem cells in several other cancers, and investigations aimed at eventually testing a similar combination antibody therapy in humans are ongoing.

In this study, the researchers were interested in learning whether leukemia stem cells play a similarly important role in acute myeloid leukemia, which is one of the most aggressive blood cancers in adults.

"We've made very little progress in the treatment of AML over the past 40 years," said Alizadeh. "We're still using the same drugs and therapies we've always used, even though about 70 percent of patients with AML die within five years of diagnosis."

The team used two cell surface markers formerly shown to identify leukemia stem cells to isolate these cells from tumor samples from seven patients. They then compared the overall gene expression patterns of the stem cells to other cells in the tumors and identified a total of 52 genes whose expression varies between the tumor stem cells and non-stem cells.

Interestingly, the gene expression pattern is similar to that found on normal blood stem cells, which give rise to blood cells and the immune system. This similarity implies that the cancer stem cells not only can self-renew, but also that they, like normal stem cells, don't divide unless they're needed. Infrequent division may be one way the cancer stem cells escape many conventional treatments that target rapidly dividing cells.

"It's as if these cells are lurking in the background, waiting to pounce after chemotherapy has wiped out most of the other cells," said Alizadeh.

When the researchers compared the levels of expression of these new leukemia stem-cell-associated genes among tumor samples from four groups with a total of more than 1,000 people with acute myeloid leukemia, they found a strong correlation between high levels of expression and a poor outcome for the patients. In one group from Germany, patients with high levels of gene expression had an absolute risk of death within three years of 78 percent, versus 57 percent for patients with lower levels of expression. High-expressing patients fared similarly poorly in comparisons of "event-free survival," or likelihood of relapse within a certain time period, and in how strongly their disease resisted initial rounds of treatment.

"The stronger the leukemia stem cell signal, the worse the patients did," said Gentles, who is a member of the Stanford Center for Cancer Systems Biology. "Their lives were shorter, they relapsed sooner and they were less able to respond to therapy." The center was established with a $12 million grant from the National Institutes of Health to stimulate the application of computer modeling to cancer research. Plevritis is the director of the center and a co-author of the research.

Plevritis and Gentles plan to study the gene expression pattern in the leukemia stem cells to identify important regulatory pathways that might be driving the cellular hierarchy in the cancer. The researchers are also working to develop ways to make their findings more useful in the clinic.

"It's difficult to measure the expression of this many genes in the clinic," said Gentles. "We'd like to try to whittle that panel of genes down to a more manageable three or four that are still prognostically important."

Finally, the team will continue to study the data to determine which treatments are most effective for patients with the high-expressing gene signature. "We'd like to know whether a group of patients with a high leukemic stem cell burden would respond well to certain types of therapy," said Gentles, "and which should be avoided. For example, bone marrow transplant can sometimes be an effective way to treat AML. But transplant itself carries significant risks for the patient. If it is not likely to help someone with high levels of expression of these genes, then we can try other approaches."

"This finding adds to our clinical confidence that the cancer stem cell hypothesis is important to human disease," said Majeti. "It may also define features of the disease that will help us to determine whether individual patients should participate in clinical trials or if their initial treatment should be more aggressive than the standard approach."

Stanford University Medical Center

---

---

	Stem Cells For Dummies by Lawrence S.B. Goldstein (Author), Meg Schneider (Author) The first authoritative yet accessible guide to this controversial topicStem Cell Research For Dummies offers a balanced, plain-English look at this politically charged topic, cutting away the hype and presenting the facts clearly for you, free from debate. It explains what stem cells are and what they do, the legalities of harvesting them and using them in research, the latest research findings from the U.S. and abroad, and the prospects for medical stem cell therapies in the short and long term.Explains the differences between adult stem cells and embryonic/umbilical cord stem cellsProvides both sides of the political debate and the pros and cons of each side's opinionsIncludes medical success stories using stem cell therapy and its promise for the futureComprehensive and unbiased, Stem...
	Essentials of Stem Cell Biology, Second Edition by Robert Lanza (Editor), John Gearhart (Editor), Brigid Hogan (Editor), Douglas Melton (Editor), Roger Pederson (Editor), E. Donnall Thomas (Editor), James Thomson (Editor), Sir Ian Wilmut (Editor) First developed as an accessible abridgement of the successful Handbook of Stem Cells, Essentials of Stem Cell Biology serves the needs of the evolving population of scientists, researchers, practitioners and students that are embracing the latest advances in stem cells. Representing the combined effort of seven editors and more than 200 scholars and scientists whose pioneering work has defined our understanding of stem cells, this book combines the prerequisites for a general understanding of adult and embryonic stem cells with a presentation by the world's experts of the latest research information about specific organ systems. From basic biology/mechanisms, early development, ectoderm, mesoderm, endoderm, methods to application of stem cells to specific human diseases, regulation and...
	The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives by Alice Park (Author) A landmark book by the senior science writer at Time magazine introduces us to a medical breakthrough that can save our lives. Few people know much about stem cell research beyond the ethical questions raised by using embryos. But in the last decade, stem cell research has made huge advances toward eliminating some of our most intractable diseases. Now this sweeping and accessible book introduces us to this cutting-edge science that will revolutionize medicine and change the way we think about and treat disease. Alice Park takes us from stem cell's controversial beginnings to the recent electrifying promise of being able to create the versatile cells without using embryos at all. She shows us how stem cells give researchers an unprecedented ability to study disease while...
	Stem Cells: A Very Short Introduction by Jonathan Slack (Author) Embryonic stem cells have been hot-button topics in recent years, generating intense public interest as well as much confusion and misinformation. In this Very Short Introduction, leading authority Jonathan Slack offers a clear and informative overview of stem cells--what they are, what scientists do with them, what stem cell therapies are available today, and how they might be used in the future. Slack explains the difference between embryonic stem cells, which exist only in laboratory cultures, and tissue-specific stem cells, which exist in our bodies, and he discusses how embryonic stem cells may be used in the future to treat such illnesses as diabetes, Parkinson's disease, heart disease, spinal trauma, and retinal degeneration. But he stresses that, despite important advances, the...
	Stem Cell Now by Christopher Thomas Scott (Author) While many believe stem cell research holds the key to curing a wide range of ailments, others see this research as opening a Pandora’s box that will devalue human life. In Stem Cell Now, Christopher Scott—executive director of Stanford University’s Stem Cells and Society Program—lays out the scientific and ethical issues surrounding this national dilemma. Scott guides readers through the latest advances in stem cell research in clear, accessible language, telling the stories of the researchers who are exploring the potential of stem cells to cure cancer, grow new organs, and repair the immune system. He also leads readers through a discussion of the question at the heart of the explosive ethical debate: How, as a society, do we balance our responsibilities to the unborn and the...
	Stem Cells: Scientific Facts and Fiction by Christine Mummery (Author), Ian Sir Wilmut (Author), Anja Van De Stolpe (Author), Bernard Roelen (Author) In the past decades our understanding of stem cell biology has increased tremendously. Many types of stem cells have been discovered in tissues of which everyone presumed were unable to regenerate in adults; these include particularly the heart and the brain. There is vast interest in stem cells from biologists and clinicians who see the potential for regenerative medicine and future treatments for chronic diseases like Parkinson, diabetes and spinal cord lesions based on the use of stem cells and entrepreneurs in biotechnology who expect new commercial applications ranging from drug discovery to transplantation therapies. As is often the case in science, many early claims turned out to be different from those expected. Embryonic stem cell therapies have not moved rapidly into clinical...
	Human Stem Cell Technology and Biology: A Research Guide and Laboratory Manual by Gary S. Stein (Editor), Maria Borowski (Editor), Mai X. Luong (Editor), Meng-Jiao Shi (Editor), Kelly P. Smith (Editor), Priscilla Vazquez (Editor) Human Stem Cell Technology & Biology: A Research Guide and Laboratory Manual integrates readily accessible text, electronic and video components with the aim of effectively communicating the critical information needed to understand and culture human embryonic stem cells.Key Features:An authoritative, comprehensive, multimedia training manual for stem cell researchersEasy to follow step-by-step laboratory protocols and instructional videos provide a valuable resourceA must-have for developing laboratory course curriculums, training courses, and workshops in stem cell biologyPerspectives written by the world leaders in the fieldIntroductory chapters will provide background informationThe volume will be a valuable reference resource for both experienced investigators pursuing stem cell and...
	Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science Roger M. Nocera, M.D., a world leader in stem cell therapy research, announces a breakthrough medical science discovery that will revolutionize health care as we know it. In his new book "Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science," Dr. Nocera reveals that a medical science discovery made in 2003 has been developed in medical clinics around the world and proven to be effective in the treatment of many heretofore incurable diseases. Cells That Heal Us From Cradle To Grave explains how this medical science discovery is on a par with Immunology discovered two centuries ago with the smallpox vaccine, and with the discovery of antibiotics a century later. Dr. Nocera’s book is a primer on how this amazing new medical...
	Essential Stem Cell Methods (Reliable Lab Solutions) by Robert Lanza (Editor), Irina Klimanskaya (Editor) As part of the Reliable Lab Solutions series, this volume offers an abridged and comprehensive update of selected chapters that first appeared in the three-volume stem cell series published in Methods in Enzymology. Currently, stem cells are of great interest to scientists and clinicians due to their unique ability to differentiate into various tissues of the body, making them a promising source of cells for regenerative medicine and drug discovery as well as an excellent model of vertebrate development. Essential Stem Cell Methods features a detailed set of protocols written by experts in the field and hand-selected by the editors to help researchers drive advances in this fast-moving field. The result is a clear set of step-by-step methods which steer the reader through the...
	Blocked In The USA: The Stem Cell Miracle by Dr William Rader (Author) If you thought the time of dramatic evolutionary advancement in medical knowledge was over, brace yourself for the untold story of a doctor who singlehandedly, in the face of disdain from his colleagues and threats from government bureaucrats, made a breakthrough scientific discovery. Dr. Rader discovered how to apply fetal stem cell technology to humans and has eased the suffering and at times saved the lives of more than 1,500 patients with Autism, Epilepsy, Multiple Sclerosis, Stroke, Parkinson's disease, Muscular Dystrophy, and many other diseases since 1995.Dr. Rader, familiar to millions as a respected medical expert on ABC-TV, reveals the astounding truth about the most extensive fetal stem cell trials ever conducted on human patients - mostly so - called "hopeless" cases. Blocked...